A comparative study of efficacy of atorvastatin, rosuvastatin, and atorvastatin + fibrates as lipid lowering agents

Authors

  • Karunasree Nagarur Department of Pharmacology, Government Medical College, Nizamabad, Telangana, India
  • Yamini Vadlamannati Department of Pharmacology, Government Medical College, Nizamabad, Telangana, India
  • Narasimha Rao Raja Health Director, Central Hospital, S C Railway, Secundrabad, Telangana, India

DOI:

https://doi.org/10.18203/2319-2003.ijbcp20163213

Keywords:

Atorvastatin, Rosuvastatin, Atorvastatin Fibrates, LDL (low density cholesterol), TG (triglycerides), HDL (high density cholesterol), TC (total cholesterol)

Abstract

Background: Hypercholesterolemia patients are at high risk of coronary heart disease. National cholesterol education programme (NCEP) Adult Treatment Panel III guidelines provide the option of aggressively lowering Low-density cholesterol in them. Presently the standard therapy of hypercholesterolemia is by HMG co-A reductase inhibitors. Present study shows that Rosuvastatin is better than Atorvastatin, Atorvastatin and Fibrate is better than Atorvastatin monotherapy in management of hypercholesterolemia.

Methods: The present research was an observational study conducted at Government general hospital, Nizamabad. A total of 150 patients on treatment for hypercholesterolemia for more than one year were enrolled in our study. They were divided into three groups. Group I: Atorvastatin (20 mg) (n=96; 64%); Group II: Rosuvastatin 10 mg (n= 41; 27.33%); Group III: Atorvastatin (20 mg) + Fibrate (145 mg) (n=13; 8.66%).

Results: Rosuvastatin is better than Atorvastatin and Atorvastatin with fibrates reduces LDL, TG more than Atorvastatin alone.

Conclusions: Rosuvastatin is better than Atorvastatin and Combination of atorvastatin with fibrates reduces LDL-Cholesterol and triglycerides more than atorvastatin alone.

References

Hunninghake DB, Ballantyne CM, Maccubbin DL. Comparative effects of simvastatin and atorvastatin in hypercholesterolemic patients with characteristics of metabolic syndrome. Clinical therapeutics 2003;25:1670-86.

Carmena R, Duriez P, Fruchart JC. Atherogenic lipoprotein particles in atherosclerosis. Circulation. 2004;109(23):2-7.

Kontush A, Chapman MJ. Antiatherogenic small, dense HDL-guardian angel of the arterial wall. Mar2006. Nat Clin Pract Cardiovasc Med. 2006;3(3):144-53.

Lella M, Indira K.. A comparative study of efficacy of atorvastatin alone and its combination with fenofibrate on lipid profile in type 2 diabetes mellitus patients with hyperlipidemia. J Adv Pharm Technol Res. 201;4(3):166-70.

Adsule SM, Baig MS, Gade PR, Khandelwal PN. Comparative evaluation of safety and efficacy of rosuvastatin, simvastatinand atorvastatin in patients of type 2 diabetes mellitus with dyslipidemia.In J Diab Dev Ctries. 2009;29(2):74-9.

Bener A, Dogan M, Barakat L, Abdulla OAA Al-Hamaq. Comparison of efficacy, safety, and cost effectiveness of various statins in dyslipidemic diabetic patients. IJP. 2014;46(1):88-93.

Barakat L, Jayyousi M, Bener A, Zuby B, Zirie M. . Comparison of Efficacy and Safety of Rosuvastatin, Atorvastatin and Pravastatin among Dyslipidemic Diabetic Patients. ISRN Pharmacol. 2013;2013:1-7.

Stalenhoef AFH, Christie M. Ballantyne, Cinzia Sarti3, Jan Murin, Serena Tonstad,Helen Rose, and Wim Wilpshaar. A COmparative study with rosuvastatin in subjects with METabolic Syndrome: results of the COMETS study. 2005;26(24):2664-72.

Arshad AR. Comparison of Low-Dose Rosuvastatin with Atorvastatin in Lipid-Lowering Efficacy and Safety in a High-Risk Pakistani Cohort: An Open-Label Randomized Trial. Journal of Lipids. 2014;2014:1-5.

Khan MA, Murti K, Grover V. Atorvastatin vs Rosuvastatin; fenofibrate as an add on: an exploratory study. Int J of Pharmacy and pharmaceutical. 2014;6(8)493-8.

Eliasson B, Svensson A-M, Miftaraj M, Miao Jonasson J.Clinical Use and Effectiveness of Lipid Lowering Therapies in Diabetes Mellitus—An Observational Study from the Swedish National Diabetes Register. Plos one. 2011;6(4):18744.

Clearfield MB, Amerena J, Jean-Pierre B. Comparison of the efficacy and safety of rosuvastatin 10 mg and atorvastatin 20 mg in high-risk patients with hypercholesterolemia – Prospective study to evaluate the Use of Low doses of the Statins Atorvastatin and Rosuvastatin (PULSAR). Eur Heart J. 2005;26(24):2664-72.

Karalis DG, Victor B, Ahedor L, Liu L. Use of Lipid-Lowering Medications and the Likelihood of Achieving Optimal LDL-Cholesterol Goals in Coronary Artery Disease Patients. Cholesterol. 2012;2012:1-7.

Downloads

Published

2017-01-10

How to Cite

Nagarur, K., Vadlamannati, Y., & Raja, N. R. (2017). A comparative study of efficacy of atorvastatin, rosuvastatin, and atorvastatin + fibrates as lipid lowering agents. International Journal of Basic & Clinical Pharmacology, 5(5), 1924–1928. https://doi.org/10.18203/2319-2003.ijbcp20163213

Issue

Section

Original Research Articles